Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
First Wave BioPharma, Inc. FWBI
$2.64
-$0.27 (-10.27%)
На 18:05, 12 мая 2023
+10 127.27%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
4462326.00000000
-
week52high
94.50
-
week52low
2.21
-
Revenue
0
-
P/E TTM
0
-
Beta
1.65986100
-
EPS
-19.50000000
-
Last Dividend
0.00000000
-
Next Earnings Date
22 мая 2023 г. в 04:00
Описание компании
First Wave BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of targeted and non-systemic therapies for the treatment of patients with gastrointestinal diseases. Its product candidates include niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties; and the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients. The company develops FW-COV, which is in Phase II clinical trials for the treatment of severe acute respiratory syndrome coronavirus 2 gastrointestinal infections; FW-UP, which is in Phase II clinical trials for the treatment ulcerative proctitis and ulcerative proctosigmoiditis; FW-ICI-AC for immune checkpoint inhibitor-associated colitis and diarrhea in advanced stage oncology patients; and FW-UC, which is in Phase Ib/IIa clinical trials for the treatment of ulcerative proctitis and ulcerative proctosigmoiditis. It also develops FW-CD, which has completed Phase I clinical trials for Crohn's disease; and adrulipase, an oral, non-systemic, and biologic capsule for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis. The company was formerly known as AzurRx BioPharma, Inc. and changed its name to First Wave BioPharma, Inc. in September 2021. First Wave BioPharma, Inc. was incorporated in 2014 and is headquartered in Boca Raton, Florida.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Roth Capital | Buy | Buy | 26 мая 2022 г. |
| Maxim Group | Hold | Buy | 07 дек 2021 г. |
| HC Wainwright & Co. | Buy | Buy | 02 дек 2022 г. |
| HC Wainwright & Co. | Buy | 03 февр 2023 г. | |
| HC Wainwright & Co. | Buy | 31 янв 2023 г. | |
| HC Wainwright & Co. | Buy | 26 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| SAPIRSTEIN JAMES | A | 300000 | 300000 | 03 янв 2023 г. |
| Romano Sarah | A | 150000 | 150000 | 03 янв 2023 г. |
| Coelho Mary Theresa | A | 84745 | 84745 | 03 янв 2023 г. |
| BORKOWSKI EDWARD | A | 86156 | 84745 | 03 янв 2023 г. |
| Riddell Alastair | A | 85185 | 84745 | 03 янв 2023 г. |
| CASAMENTO CHARLES J | A | 85134 | 84745 | 03 янв 2023 г. |
| Hoffman David Andrew | A | 90778 | 84745 | 03 янв 2023 г. |
| Romano Sarah | A | 150000 | 150000 | 01 мар 2022 г. |
| Schramm Vern Lee | A | 34482 | 34482 | 03 янв 2022 г. |
| Schneiderman Daniel H | A | 10000 | 10000 | 03 янв 2022 г. |
Новостная лента
First Wave BioPharma to Present at the BIO CEO & Investor Conference
GlobeNewsWire
30 янв 2023 г. в 07:00
BOCA RATON, Fla., Jan. 30, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced James Sapirstein, Chairman, President and CEO, will present at the BIO CEO & Investor Conference being held February 6-9, 2023, at the Marriott Marquis in New York City.
Why Is First Wave BioPharma (FWBI) Stock Up 30% Today?
InvestorPlace
25 янв 2023 г. в 11:36
Many Nasdaq stocks were in the red this morning, but not First Wave BioPharma (NASDAQ: FWBI ) stock. Indeed, First Wave shares were up substantially after the company announced an addition to its intellectual property (IP) portfolio governing a proprietary drug called adrulipase.
First Wave BioPharma to Present at Sequire Biotechnology Conference
GlobeNewsWire
24 янв 2023 г. в 07:00
BOCA RATON, Fla., Jan. 24, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced James Sapirstein, Chairman, President and CEO, will present at the Sequire Biotechnology Conference being held virtually on February 2, 2023.
First Wave (FWBI) IND Filing Under FDA's Review, Stock Up
Zacks Investment Research
16 янв 2023 г. в 14:18
First Wave's (FWBI) stock gains as FDA reviews its IND amendment for the planned phase II study of an enhanced enteric microgranule delivery formulation of adrulipase.
First Wave BioPharma's CEO James Sapirstein to Present at Inaugural Roth Healthcare Opportunities Conference
GlobeNewsWire
28 сент 2022 г. в 07:00
BOCA RATON, Fla., Sept. 28, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that James Sapirstein, Chairman, President, and CEO of First Wave BioPharma, will give a presentation and take investor meetings at the Inaugural Roth Healthcare Opportunities Conference taking place October 6, 2022, in New York City.